Hans-Christian Kolberg, MD: The Importance of Reporting Data on Biosimilar Trastuzumab

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, reflects on the importance of reporting new cardiac data from the LILAC trial of ABP 980, a trastuzumab biosimilar.
June 06, 2019



Transcript

I think it is very important to keep reporting these things because, even for people doing oncology for years and decades, it’s still very difficult to really differentiate between a generic medication and a biosimilar. A generic is simply like cooking the same recipe, and developing a biosimilar is completely different. It’s really developing a new medication; you just do it the other way around. It is reverse-engineering because you have to find out what the original company was doing.

The effect regarding healthcare economics is that, of course, you can sell that cheaper because developing a new antibody is an investment of more than $1 billion usually, whereas developing a biosimilar for a known antibody costs about $200 million dollars.

So actually the prices in the end are cheaper, which is of course important in countries like the United States or in Germany, where I work, because we save money we can use for other things in the healthcare system. But it's even more important in places where giving a patient an antibody is not a question because there's no money for that. Like in the developing countries. For those, biosimilars may be a huge chance to gain access to antibodies at all.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.